Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Shattuck Labs, Inc.
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Transgene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Elicio Therapeutics
Institut Bergonié
Masonic Cancer Center, University of Minnesota
Sichuan Enray Pharmaceutical Sciences Company
University of Kentucky
Pfizer
University of Pennsylvania
Boehringer Ingelheim
Shattuck Labs, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
Kazia Therapeutics Limited
Avera McKennan Hospital & University Health Center
Pfizer
ADC Therapeutics S.A.
Pfizer
Gilead Sciences
Mayo Clinic
Pfizer
Hoffmann-La Roche
Brown University
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Herlev Hospital
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Five Prime Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Pfizer
EMD Serono
PharmaMar
Ipsen
Dana-Farber Cancer Institute
Novartis
Almac Discovery
Takeda
Pfizer